Market Overview

Advaxis Signs License Agreement for Development and Commercialization of ADXS-HPV in Asia


Advaxis (NASDAQ: ADXS) announced that it has entered into an exclusive
licensing agreement for the development and commercialization of
ADXS-HPV with Global BioPharma, Inc. (GBP), a Taiwanese based biotech
company funded by a group of investors led by Taiwan Biotech Co., Ltd
(TBC). TBC is one of the top five pharmaceutical companies in Taiwan and
formed GBP solely to focus on the development and commercialization of
ADXS-HPV for the treatment of human papillomavirus (HPV)-associated
diseases. The GBP territory covers over 4 billion people with over
200,000 annual diagnoses of cervical cancer, accounting for roughly 40%
of the world's cases, according to WHO statistics.

See full press release

Posted-In: News Guidance Management Global


Related Articles (ADXS)

View Comments and Join the Discussion!

Partner Center